Oral Answers to Questions

Neil O'Brien Excerpts

Wednesday 10th April 2019 Commons Chamber

[The Prime Minister]

I refer the hon. Gentleman to the answers I gave earlier in relation to universal credit and the importance of this system, which is encouraging people into work—200,000 more people are in work under universal credit and 700,000 people are getting money that they were entitled to but not receiving before. Universal credit is helping people into work and making sure that work pays.

[Neil O’Brien (Harborough) (Con)]

My constituents Mark and Panna Wilson have a little son, Aadi, who has the terrible condition of spinal muscular atrophy. He desperately needs the life-changing drug Spinraza, which is available in many other countries. I know that the Health Secretary is working on this urgently. Will the Prime Minister intervene to create a new route to market for this important drug, so that my constituents can get the life-saving treatment that their son needs?

[The Prime Minister]

My hon. Friend has raised an important issue. Obviously, as he will appreciate, it is important that we ensure, first, that patients get access to cost-effective innovative medicines, but at a price that is fair and makes best use of NHS resources. That is the independent system that we have through the National Institute for Health and Care Excellence, which reviews the evidence. I understand that Biogen has submitted a revised submission to NICE in relation to Spinraza and that a meeting of NICE’s independent appraisal committee took place early in March to consider its recommendations. It is clear that everyone at the Department of Health and Social Care and in NICE recognises the significance of this drug, but we need to ensure that the decision taken is made on the basis of the clinical aspects, together with cost-effectiveness. That is what NICE will do in looking at the new offer.